|
EP0711804A3
(de)
|
1994-11-14 |
1999-09-22 |
Ciba SC Holding AG |
Kryptolichtschutzmittel
|
|
JP3512911B2
(ja)
|
1995-07-11 |
2004-03-31 |
富士写真フイルム株式会社 |
紫外線吸収剤前駆体化合物、それを含有する感光性樹脂組成物及び画像形成方法
|
|
CN1129597C
(zh)
|
1997-07-24 |
2003-12-03 |
全药工业株式会社 |
杂环化合物和以其为有效成分的抗肿瘤剂
|
|
JPH11174638A
(ja)
|
1997-12-08 |
1999-07-02 |
Konica Corp |
ハロゲン化銀カラー写真感光材料
|
|
US6777439B2
(en)
|
2000-05-30 |
2004-08-17 |
Advanced Research & Technology Institute, Inc. |
Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
|
|
DE60217322T2
(de)
|
2001-04-27 |
2007-10-04 |
Zenyaku Kogyo K.K. |
Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
|
|
DE10207037A1
(de)
|
2002-02-20 |
2003-08-28 |
Bayer Cropscience Gmbh |
2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
|
|
US6846928B2
(en)
|
2002-03-15 |
2005-01-25 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
US20040009981A1
(en)
|
2002-03-15 |
2004-01-15 |
David Bebbington |
Compositions useful as inhibitors of protein kinases
|
|
DE60332433D1
(de)
|
2002-03-15 |
2010-06-17 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
|
EP1485381B8
(en)
|
2002-03-15 |
2010-05-12 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazine as inhibitors of protein kinases
|
|
US20070191402A1
(en)
|
2002-05-17 |
2007-08-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of searching substrate having antidiabetic activity
|
|
CA2503451C
(en)
|
2002-10-25 |
2011-07-12 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compounds and antitumor agent comprising the same as effective component
|
|
EA013811B1
(ru)
|
2002-11-21 |
2010-08-30 |
Новартис Вэксинес Энд Дайэгностикс, Инк. |
2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
|
|
WO2005028467A1
(en)
|
2003-09-15 |
2005-03-31 |
Anadys Pharmaceuticals, Inc. |
Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
|
|
DK1704145T3
(da)
|
2004-01-12 |
2012-09-24 |
Ym Biosciences Australia Pty |
Selektive kinaseinhibitorer
|
|
JP4733021B2
(ja)
|
2004-03-31 |
2011-07-27 |
全薬工業株式会社 |
複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤
|
|
ES2355923T3
(es)
|
2004-08-26 |
2011-04-01 |
Pfizer, Inc. |
Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
|
|
WO2006053227A2
(en)
|
2004-11-10 |
2006-05-18 |
Synta Pharmaceuticals Corp. |
Il-12 modulatory compounds
|
|
TW200628463A
(en)
|
2004-11-10 |
2006-08-16 |
Synta Pharmaceuticals Corp |
Heteroaryl compounds
|
|
CN101137382B
(zh)
|
2005-03-11 |
2012-11-21 |
全药工业株式会社 |
含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂
|
|
GB0525081D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0525080D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
US20070244110A1
(en)
|
2006-04-14 |
2007-10-18 |
Zenyaku Kogyo Kabushiki Kaisha |
Treatment of prostate cancer, melanoma or hepatic cancer
|
|
TW200801012A
(en)
|
2006-04-26 |
2008-01-01 |
Piramed Ltd |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
|
TWI498332B
(zh)
|
2006-04-26 |
2015-09-01 |
Hoffmann La Roche |
作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
|
|
EP2050749B1
(en)
|
2006-08-08 |
2017-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
Pyrimidine derivative as pi3k inhibitor and use thereof
|
|
WO2008032036A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032091A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032060A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
|
|
CN101595103A
(zh)
|
2006-09-14 |
2009-12-02 |
阿斯利康(瑞典)有限公司 |
嘧啶衍生物
|
|
WO2008032089A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032041A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives having inhibitory activity against pi3k enzymes
|
|
WO2008032077A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
CN101535296A
(zh)
|
2006-09-14 |
2009-09-16 |
阿斯利康(瑞典)有限公司 |
作为p13k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-苯基嘧啶衍生物
|
|
EP2064203A1
(en)
|
2006-09-14 |
2009-06-03 |
AstraZeneca AB |
2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032033A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032027A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
JP2010503648A
(ja)
|
2006-09-14 |
2010-02-04 |
アストラゼネカ アクチボラグ |
増殖性疾患の治療のためのｐｉ３ｋ及びｍｔｏｒ阻害剤としての２−ベンゾイミダゾリル−６−モルホリノ−４−（アゼチジン、ピロリジン、ピペリジン、又はアゼピン）ピリミジン誘導体
|
|
WO2008098058A1
(en)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Pi 3-kinase inhibitors and methods of their use
|
|
WO2008110891A2
(en)
|
2007-03-09 |
2008-09-18 |
Orchid Research Laboratories Limited, |
New heterocyclic compounds
|
|
US20080233127A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
|
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
|
EP2166849A4
(en)
|
2007-06-11 |
2010-09-15 |
Miikana Therapeutics Inc |
SUBSTITUTED PYRAZOL COMPOUNDS
|
|
BRPI0814503A2
(pt)
|
2007-07-09 |
2017-05-16 |
Astrazeneca Ab |
composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
|
|
WO2009045174A1
(en)
|
2007-10-05 |
2009-04-09 |
S*Bio Pte Ltd |
2-morpholinylpurines as inhibitors of pi3k
|
|
EP2209786B1
(en)
|
2007-10-05 |
2013-02-27 |
Verastem, Inc. |
Pyrimidine substituted purine derivatives
|
|
ES2539714T3
(es)
|
2007-11-22 |
2015-07-03 |
Zenyaku Kogyo Kabushikikaisha |
Dispersiones sólidas que comprenden un cuerpo amorfo compuesto por un compuesto antitumoral heterocíclico
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
CA2712267A1
(en)
|
2008-01-15 |
2009-07-23 |
Wyeth Llc |
3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
WO2009093981A1
(en)
|
2008-01-23 |
2009-07-30 |
S Bio Pte Ltd |
Triazine compounds as kinase inhibitors
|
|
US20090192176A1
(en)
|
2008-01-30 |
2009-07-30 |
Wyeth |
1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
|
|
CL2009000241A1
(es)
|
2008-02-07 |
2010-09-03 |
Chugai Pharmaceutical Co Ltd |
Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
|
|
JP2011515462A
(ja)
|
2008-03-27 |
2011-05-19 |
アウククランド ウニセルビセス リミテッド |
置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
|
|
LT2294072T
(lt)
|
2008-05-23 |
2017-06-12 |
Wyeth Llc |
Triazino junginiai, kaip p13 kinazės ir mtor inhibitoriai
|
|
US20110105500A1
(en)
|
2008-06-27 |
2011-05-05 |
S*Bio Pte Ltd. |
Pyrazine substituted purines
|
|
US8513221B2
(en)
|
2008-07-07 |
2013-08-20 |
Xcovery Holding, LLC |
PI3K isoform selective inhibitors
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
KR20160091440A
(ko)
|
2008-11-13 |
2016-08-02 |
길리아드 칼리스토가 엘엘씨 |
혈액 종양에 대한 요법
|
|
JPWO2010092962A1
(ja)
|
2009-02-12 |
2012-08-16 |
アステラス製薬株式会社 |
へテロ環誘導体
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
TW201038567A
(en)
|
2009-03-27 |
2010-11-01 |
Pathway Therapeutics Ltd |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
BRPI1009022A2
(pt)
|
2009-05-27 |
2016-03-08 |
Hoffmann La Roche |
"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
|
|
US8158625B2
(en)
|
2009-05-27 |
2012-04-17 |
Genentech, Inc. |
Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
|
|
SG176986A1
(en)
|
2009-06-25 |
2012-02-28 |
Amgen Inc |
Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
|
|
CA2765817A1
(en)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
|
|
CN102625799A
(zh)
|
2009-06-25 |
2012-08-01 |
安姆根有限公司 |
杂环化合物及其用途
|
|
AU2010265971B2
(en)
|
2009-06-25 |
2014-08-14 |
Amgen Inc. |
Heterocyclic compounds and their uses as inhibitors of PI3 K activity
|
|
CA2767008C
(en)
|
2009-07-07 |
2018-01-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
EP2604601B1
(en)
|
2010-08-10 |
2016-02-24 |
Astellas Pharma Inc. |
Hetero ring compound
|
|
AU2011338530B2
(en)
|
2010-12-06 |
2017-06-15 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
|
US9300694B2
(en)
*
|
2011-01-11 |
2016-03-29 |
INHA—Industry Partnership Institute |
Audio signal quality measurement in mobile device
|
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
|
AU2012236722A1
(en)
|
2011-03-28 |
2013-10-17 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
WO2012135166A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
TWI572599B
(zh)
|
2011-03-28 |
2017-03-01 |
Ｍｅｉ製藥公司 |
（α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
|
|
EP2723747A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
US8822469B2
(en)
|
2011-06-22 |
2014-09-02 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
|
|
US9309250B2
(en)
|
2011-06-22 |
2016-04-12 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
|
|
WO2013006408A1
(en)
|
2011-07-01 |
2013-01-10 |
Tempero Pharmaceuticals, Inc. |
Compounds and methods
|
|
WO2013068075A1
(de)
|
2011-11-11 |
2013-05-16 |
Merck Patent Gmbh |
Verfahren zur herstellung von arylaminen
|
|
AU2013299627C1
(en)
|
2012-08-09 |
2018-05-31 |
Celgene Corporation |
Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
US9963452B2
(en)
|
2013-03-14 |
2018-05-08 |
Augusta Pharmaceuticals Inc. |
Methods, compounds, and compositions for inhibition of ROS
|
|
EP2832358A1
(en)
|
2013-08-02 |
2015-02-04 |
Bionsil S.r.l. |
Pharmaceutical kit for use in the treatment of colon and colorectal cancer
|
|
CN105979948A
(zh)
|
2013-12-05 |
2016-09-28 |
安塞塔制药公司 |
Pi3k抑制剂和btk抑制剂的治疗组合
|
|
AU2015220427B2
(en)
|
2014-02-19 |
2017-09-21 |
Piramal Enterprises Limited |
Compounds for use as GPR120 agonists
|
|
US9949971B2
(en)
|
2014-06-17 |
2018-04-24 |
Acerta Pharma B.V. |
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
|
|
JP6626085B2
(ja)
|
2014-07-15 |
2019-12-25 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
|
|
TW201618774A
(zh)
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
|
|
TW201618775A
(zh)
*
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物
|
|
HUE049175T2
(hu)
|
2014-09-23 |
2020-09-28 |
Hoffmann La Roche |
Eljárás anti-CD79b immunkonjugátumok alkalmazására
|
|
BR112017013465A2
(pt)
|
2014-12-24 |
2018-03-06 |
Lg Chem, Ltd |
derivado de biarila, e, composição farmacêutica.
|
|
CA3217238A1
(en)
|
2015-07-20 |
2017-01-26 |
Genzyme Corporation |
Colony stimulating factor-1 receptor (csf-1r) inhibitors
|
|
CN105130960B
(zh)
*
|
2015-07-31 |
2018-07-06 |
沈阳药科大学 |
1,3,5-三嗪类衍生物及其应用
|
|
KR20180042356A
(ko)
|
2015-08-24 |
2018-04-25 |
에피자임, 인코포레이티드 |
암 치료 방법
|
|
US20190054090A1
(en)
*
|
2015-10-01 |
2019-02-21 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
|
WO2017066705A1
(en)
|
2015-10-14 |
2017-04-20 |
Aquinnah Pharmaceuticals, Inc. |
Compounds, compositions and methods of use against stress granules
|
|
EP3487878A4
(en)
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
|
|
IL292938A
(en)
|
2016-09-19 |
2022-07-01 |
Mei Pharma Inc |
Combined treatment
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
US11304953B2
(en)
*
|
2017-05-23 |
2022-04-19 |
Mei Pharma, Inc. |
Combination therapy
|
|
KR20200041358A
(ko)
|
2017-08-14 |
2020-04-21 |
메이 파마, 아이엔씨. |
병용 요법
|
|
CN112165939A
(zh)
|
2018-03-21 |
2021-01-01 |
梅制药公司 |
联合疗法
|
|
SG11202101450VA
(en)
|
2018-08-14 |
2021-03-30 |
Mei Pharma Inc |
Treatment of b cell malignancies
|
|
BR112021002734A2
(pt)
|
2018-08-14 |
2021-07-20 |
Mei Pharma, Inc. |
tratamento de linfoma folicular reincidente
|
|
US20210161909A1
(en)
|
2018-08-14 |
2021-06-03 |
Mei Pharma, Inc. |
Combination therapy
|
|
TW202038945A
(zh)
|
2018-12-21 |
2020-11-01 |
美商梅製藥公司 |
組合療法
|